Enhancement of docetaxel solubility using binary and ternary solid dispersion systems

Drug Development and Industrial Pharmacy

Volumn 41, Issue 11, 2015, Pages 1847-1855

  Lim, Sue May ^a   Pang, Zyu Wenn ^a   Tan, Hwei Yuin ^a   Shaikh, Mohsin ^b   Adinarayana, Gorajana ^a   Garg, Sanjay ^b  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Anti cancer; Apparent solubility; Freeze drying; Solubility parameter; Soluplus

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; DOCETAXEL; POLOXAMER; POVIDONE; SOLUBILIZER; SOLUPLUS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EXCIPIENT; MACROGOL DERIVATIVE; POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMER; POLYVINYL DERIVATIVE; TAXOID;

ARTICLE; BINARY SOLID DISPERSION; COMPARATIVE STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUBILITY; FREEZE DRYING; INFRARED SPECTROSCOPY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; TERNARY SOLID DISPERSION; X RAY POWDER DIFFRACTION; CHEMISTRY; DRUG DELIVERY SYSTEM; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SOLUBILITY; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FREEZE DRYING; MICROSCOPY, ELECTRON, SCANNING; POLYETHYLENE GLYCOLS; POLYVINYLS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TAXOIDS; X-RAY DIFFRACTION;

EID: 84979523835     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2015.1014818     Document Type: Article

References (41)

1. Thomas VH, Bhattachar S, Hitchingham L, et al. The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol 2006;2:591-608.
2. Chen J, Qiu L, Hu M, et al. Preparation, characterization and in vitro evaluation of solid dispersions containing docetaxel. Drug Dev Ind Pharm 2008;34:588-94.
3. Moes JJ, Koolen SL, Huitema AD, et al. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int J Pharm 2011;420: 244-50.
4. Kuppens IE, Bosch TM, van Maanen MJ, et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 2005;55:72-8.
5. Gao K, Sun J, Liu K, et al. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm 2008;34:1227-37.
6. van Waterschoot RA, Lagas JS, Wagenaar E, et al. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 2009;69:8996-9002.
7. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62:6158-64
8. Sanofi-Aventis. Taxotere (docetaxel) injection. FDA/CDER; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020449s073lbl.pdf.
9. Sinha S, Ali M, Baboota S, et al. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech 2010;11:518-27.
10. Chen C, Xie X, Li Y, et al. Influence of different polymers on crystallization tendency and dissolution behavior of cilnidipine in solid dispersions. Drug Dev Ind Pharm 2014;40:441-51.
11. Forster A, Hempenstall J, Tucker, I, et al. The potential of small-scale fusion experiments and the Gordon-Taylor equation to predict the suitability of drug/polymer blends for melt extrusion. Drug Dev Ind Pharm 2001;27:549-60.
12. Chiang PC, Cui Y, Ran Y, et al. In vitro and in vivo evaluation of amorphous solid dispersions generated by different bench-scale processes, using griseofulvin as a model compound. AAPS J 2013; 15:608-17.
13. Guzman HR, Tawa M, Zhang Z, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 2007;96: 2686-702.
14. Jain S, Patel N, Lin S. Solubility and dissolution enhancement strategies: current understanding and recent trends. Drug Dev Ind Pharm 2014. [Epub ahead of print]. DOI:10.3109/03639045.2014.971027.
15. Hardung H, Djuric D, Ali S. Combining HME & solubilization: Soluplus - the solid solution. Drug Deliv Technol 2010;10:20-7.
16. Shamma RN, Basha M. Soluplus: a novel polymeric solubilizer for optimization of Carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Technol 2013;237:406-14.
17. Alhalaweh A, Alzghoul A, Kaialy W. Data mining of solubility parameters for computational prediction of drug-excipient miscibility. Drug Dev Ind Pharm 2014;40:904-9.
18. Forster A, Hempenstall J, Tucker I, et al. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm 2001;226: 147-61.
19. Thakral S, Thakral NK. Prediction of drug-polymer miscibility through the use of solubility parameter-based Flory--uggins interaction parameter and the experimental validation: PEG as model polymer. J Pharm Sci 2013;102:2254-63.
20. Taupitz T, Dressman JB, Buchanan CM, et al. Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole. Eur J Pharm Biopharm 2013;83:378-87.
21. Mishra BB, Agarwal SK, Vardhan A. Amorphous form of docetaxel. 2008; WIPO Patent Application WO/2008/102374.
22. Mohsin S, Arellano IH, Choudhury NR, et al. Docetaxel epimerization in silicone films: a case of drug excipient incompatibility. Drug Test Anal 2014;6:1076-84.
23. Garg MB, Ackland SP. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J Chromatogr B Biomed Sci Appl 2000;748: 383-8.
24. Greenhalgh DJ, Williams AC, Timmins P, et al. Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci 1999;88:1182-90.
25. Kolter K, Karl M, Gryczke A. Hot-melt extrusion with basf pharma polymers extrusion compendium. Ludwigshafen, Germany: BASF; 2012.
26. Huynh L, Grant J, Leroux JC, et al. Predicting the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods. Pharm Res 2008;25:147-57.
27. Mazzaferro S, Bouchemal K, Gallard JF, et al. Bivalent sequential binding of docetaxel to methyl-beta-cyclodextrin. Int J Pharm 2011; 416:171-80.
28. Wu J, Shen Q, Fang L. Sulfobutylether-beta-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel. Drug Dev Ind Pharm 2013;39:1010-9.
29. Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 2007;18:95-103.
30. Zaske L, Perrin M-A, Leveiller F. Docetaxel: solid state characterization by X-ray powder diffraction and thermogravimetry. J Phys IV France 2001;11:Pr10-221-Pr10-6.
31. Tatini LK, Krishna Reddy KV, Someswara Rao N. Vapor-induced phase transformations in docetaxel. AAPS PharmSciTech 2012;13: 548-55.
32. Hancock BC, York P, Rowe RC. The use of solubility parameters in pharmaceutical dosage form design. Int J Pharm 1997;148:1-21.
33. Marsac PJ, Shamblin SL, Taylor LS. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 2006;23:2417-26.
34. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci 2009;98:2549-72.
35. Kestur US, Van Eerdenbrugh B, Taylor LS. Influence of polymer chemistry on crystal growth inhibition of two chemically diverse organic molecules. CrystEngComm 2011;13:6712-18.
36. Raghavan SL, Trividic A, Davis AF, et al. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm 2001; 212:213-21.
37. Saenger W, Muller-Fahrnow A. Cyclodextrins increase surface tension and critical micelle concentrations of detergent solutions. Angew Chem Int Ed Engl 1988;27:393-4.
38. García-Río L, Méndez M, Paleo MR, et al. New insights in cyclodextrin: surfactant mixed systems from the use of neutral and anionic cyclodextrin derivatives. J Phys Chem B 2007;111: 12756-64.
39. Lee TW, Boersen NA, Yang G, et al. Evaluation of different screening methods to understand the dissolution behaviors of amorphous solid dispersions. Drug Dev Ind Pharm 2014;40: 1072-83.
40. Aucamp M, Odendaal R, Liebenberg W, et al. Amorphous azithromycin with improved aqueous solubility and intestinal membrane permeability. Drug Dev Ind Pharm 2014. [Epub ahead of print]. DOI: 10.3109/03639045.2014.931967.
41. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006;29: 278-87.